ArticleMovement disorders clinical practice2026
Continuous Subcutaneous Foslevodopa/Foscarbidopa in Advanced Parkinson's Disease.
Article in Movement disorders clinical practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Continuous infusion therapy after deep brain stimulation in Parkinson's disease: indications, outcomes, and patient selection.Journal of neural transmission (Vienna, Austria : 1996) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundContinuous subcutaneous foslevodopa/foscarbidopa (LDp/CDp) provides 24-h delivery of levodopa-carbidopa prodrugs for advanced Parkinson's disease. Real-world 1-year European data remain limited.
objectivesTo characterize 1-year changes in motor, non-motor, autonomic, quality-of-life and sleep outcomes, and in concomitant therapy.
methodsRetrospective single-center observational study of 32 patients initiated on LDp/CDp between April 2024 and January 2026.
resultsTwenty of 32 patients (62.5%) completed 1-year follow-up. MDS-UPDRS Part III improved by 30.3%, Part IV by 36.0% and Part II by 13.2% (all significant); non-motor and autonomic totals were unchanged. Quality of life improved (p = 0.040), driven by bodily discomfort. Levodopa-equivalent dose rose by 31.7% while oral dopamine agonist use fell from 70% to 25% (p = 0.004).
conclusionsOne year of LDp/CDp was associated with substantial motor benefit and improved quality of life, achieved with higher levodopa equivalent and reduced dopamine agonist use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.